Skip to main content
. Author manuscript; available in PMC: 2021 Feb 24.
Published in final edited form as: Nat Cell Biol. 2020 Aug 24;22(9):1130–1142. doi: 10.1038/s41556-020-0560-6

Extended Data Fig. 6: Decrease in FBXL7 mRNA expression in prostate cancer is not associated with changes in c-SRC mRNA levels.

Extended Data Fig. 6:

a-d, Oncomine analysis of FBXL7 and c-SRC mRNA levels in four independent collections of normal and tumor prostate human specimens. N, normal prostate; PCa, prostate carcinoma; PA, prostate adenocarcinoma. a, n = 28 (N), n = 94 (PCa); b, n = 29 (N), n = 155 (PCa), n = 1 (PA); c, n = 13 (N), n = 44 (PCa); d, n = 8 (N), n = 32 (PCa) independent specimens. Median, 10th and 90th percentile are shown in the bar graph. P values are from unpaired, two-tailed t-test, as reported in Oncomine (www.oncomine.org).